Significant changes or cancellation of MCIT could result in limiting
access to breakthrough medical technologies that could improve the
health and well-being of Medicare beneficiaries. For these reasons, we
encourage federal agencies to work together and CMS to implement the
MCIT rule without delay to ensure timely access to breakthrough
technologies